Seeking Alpha

Galena Biopharma (GALE -18.7%) discloses the details of its unspecified secondary offering...

Galena Biopharma (GALE -18.7%) discloses the details of its unspecified secondary offering announced late yesterday, saying it sold 15.2M units for gross proceeds of about $24.3M. The units - consisting of one share of stock and a warrant - priced at $1.60 each. The warrants entitle holders to purchase half a share at an exercise price of $1.90. The company intends to use the proceeds for clinical trials of its breast cancer treatment NeuVax and a trial of its Folate Binding Protein-E39. The company has a current float of around 67.6M shares.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs